Search research articles
Contact Us
Filters
Showing results (441-450 of 649) with videos related to
Page
of 65
Sort By:
BMC Cancer
|
December 7, 2010
Assessment of a six gene panel for the molecular detection of circulating tumor cells in the blood of female cancer patients
Eva Obermayr, Fatima Sanchez-Cabo, Muy-Kheng M Tea, et al.
Anti-Cancer Drugs
|
January 19, 2005
Single-agent trastuzumab versus trastuzumab plus cytotoxic chemotherapy in metastatic breast cancer: a single-institution experience
Wolfgang J Köstler, Günther G Steger, Michael Krainer, et al.
Virchows Archiv : an International Journal of Pathology
|
August 5, 2025
HER2/CEP17 ratio predicts residual cancer burden after neoadjuvant dual HER2 blockade: real-world data in patients with primary HER2-amplified breast cancer
Myriam Stolz, Alex Farr, Kristina A Tendl-Schulz, et al.
Plos One
|
April 18, 2018
Correction: Diagnostic markers for the detection of ovarian cancer in BRCA1 mutation carriers
Daphne Gschwantler-Kaulich, Sigrid Weingartshofer, Christine Rappaport-Fürhauser, et al.
Plos One
|
March 3, 2017
PTEN expression as a predictor for the response to trastuzumab-based therapy in Her-2 overexpressing metastatic breast cancer
Daphne Gschwantler-Kaulich, Yen Y Tan, Eva-Maria Fuchs, et al.
Breast (Edinburgh, Scotland)
|
May 28, 2019
Stromal coexpression of uPA/PAI-1 protein predicts poor disease outcome in endocrine-treated postmenopausal patients with receptor-positive early breast cancer
C F Singer, M Filipits, S W Jahn, et al.
International Orthopaedics
|
March 27, 2010
Microarray analysis identifies distinct gene expression profiles associated with histological subtype in human osteosarcoma
Bernd Kubista, Florian Klinglmueller, Martin Bilban, et al.
Plos One
|
December 16, 2017
Diagnostic markers for the detection of ovarian cancer in BRCA1 mutation carriers
Daphne Gschwantler-Kaulich, Sigrid Weingartshofer, Christine Rappaport-Fürhauser, et al.
Breast Care (Basel, Switzerland)
|
October 9, 2025
New Perspectives in the Management of Triple-Negative Breast Cancer
Rupert Bartsch, Zsuzsanna Bago-Horvath, Daniel Egle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 12, 2004
Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer
Wolfgang J Köstler, Barbara Schwab, Christian F Singer, et al.
Page
of 65
Search research articles
Search
Showing results (441-450 of 649) with videos related to
Sort By:
Page
of 65
BMC Cancer
|
December 7, 2010
Assessment of a six gene panel for the molecular detection of circulating tumor cells in the blood of female cancer patients
Eva Obermayr, Fatima Sanchez-Cabo, Muy-Kheng M Tea, et al.
Anti-Cancer Drugs
|
January 19, 2005
Single-agent trastuzumab versus trastuzumab plus cytotoxic chemotherapy in metastatic breast cancer: a single-institution experience
Wolfgang J Köstler, Günther G Steger, Michael Krainer, et al.
Virchows Archiv : an International Journal of Pathology
|
August 5, 2025
HER2/CEP17 ratio predicts residual cancer burden after neoadjuvant dual HER2 blockade: real-world data in patients with primary HER2-amplified breast cancer
Myriam Stolz, Alex Farr, Kristina A Tendl-Schulz, et al.
Plos One
|
April 18, 2018
Correction: Diagnostic markers for the detection of ovarian cancer in BRCA1 mutation carriers
Daphne Gschwantler-Kaulich, Sigrid Weingartshofer, Christine Rappaport-Fürhauser, et al.
Plos One
|
March 3, 2017
PTEN expression as a predictor for the response to trastuzumab-based therapy in Her-2 overexpressing metastatic breast cancer
Daphne Gschwantler-Kaulich, Yen Y Tan, Eva-Maria Fuchs, et al.
Breast (Edinburgh, Scotland)
|
May 28, 2019
Stromal coexpression of uPA/PAI-1 protein predicts poor disease outcome in endocrine-treated postmenopausal patients with receptor-positive early breast cancer
C F Singer, M Filipits, S W Jahn, et al.
International Orthopaedics
|
March 27, 2010
Microarray analysis identifies distinct gene expression profiles associated with histological subtype in human osteosarcoma
Bernd Kubista, Florian Klinglmueller, Martin Bilban, et al.
Plos One
|
December 16, 2017
Diagnostic markers for the detection of ovarian cancer in BRCA1 mutation carriers
Daphne Gschwantler-Kaulich, Sigrid Weingartshofer, Christine Rappaport-Fürhauser, et al.
Breast Care (Basel, Switzerland)
|
October 9, 2025
New Perspectives in the Management of Triple-Negative Breast Cancer
Rupert Bartsch, Zsuzsanna Bago-Horvath, Daniel Egle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 12, 2004
Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer
Wolfgang J Köstler, Barbara Schwab, Christian F Singer, et al.
Page
of 65